EDROPHONIUM CHLORIDE PRESERVATIVE FREE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EDROPHONIUM CHLORIDE PRESERVATIVE FREE (EDROPHONIUM CHLORIDE PRESERVATIVE FREE).
Inhibits acetylcholinesterase, prolonging the action of acetylcholine at nicotinic and muscarinic receptors, enhancing neuromuscular transmission.
| Metabolism | Primarily metabolized by plasma esterases; minimal hepatic metabolism. |
| Excretion | Primarily renal excretion of unchanged drug (approximately 70-80%) with minor biliary excretion (10-15%). |
| Half-life | Terminal elimination half-life is 1-2 hours in healthy adults; prolonged up to 4-6 hours in renal impairment. |
| Protein binding | Low (~10-20%), primarily to albumin. |
| Volume of Distribution | Approximately 0.3-0.5 L/kg, reflecting distribution primarily in extracellular fluid. |
| Bioavailability | Not applicable; administered IV or IM only (no oral formulation). |
| Onset of Action | IV: 30-60 seconds; IM: 2-5 minutes. |
| Duration of Action | IV: 5-15 minutes; IM: 10-30 minutes. Duration is short due to rapid redistribution and elimination. |
2 mg intravenous (IV) or intramuscular (IM) as a test dose; for myasthenia gravis diagnosis: 2 mg IV test dose followed by 8 mg IV after 30 seconds if no reaction; for myasthenic crisis: 2 mg IV; for reversal of nondepolarizing neuromuscular blockade: 0.5-1 mg/kg IV.
| Dosage form | INJECTABLE |
| Renal impairment | For GFR 10-50 mL/min: administer 50% of dose; for GFR <10 mL/min: avoid use or administer 25% of dose with caution. |
| Liver impairment | No specific Child-Pugh based dose adjustments; use with caution in severe hepatic impairment due to potential for reduced clearance. |
| Pediatric use | For myasthenia gravis diagnosis: 0.1-0.2 mg/kg IV/IM (max 10 mg) as a test dose; for myasthenic crisis: 0.1 mg/kg IV; for reversal of nondepolarizing neuromuscular blockade: 0.5-1 mg/kg IV. |
| Geriatric use | Dose as for adults; monitor for bradycardia, hypotension, and bronchospasm due to increased sensitivity and potential comorbidities. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for EDROPHONIUM CHLORIDE PRESERVATIVE FREE (EDROPHONIUM CHLORIDE PRESERVATIVE FREE).
| Breastfeeding | Edrophonium is poorly excreted into breast milk due to its quaternary structure and low lipid solubility. M/P ratio is unknown but expected to be low. No adverse effects in nursing infants have been reported. Breastfeeding is acceptable with monitoring for infant cholinergic effects (e.g., diarrhea, increased secretions). |
| Teratogenic Risk | Edrophonium chloride is a quaternary ammonium compound with limited placental transfer. Animal studies have not shown teratogenic effects, but human data are insufficient to establish safety. First trimester exposure is not associated with major congenital malformations. Second and third trimester use may cause transient fetal bradycardia and muscle weakness due to cholinergic effects. Risk cannot be excluded. |
■ FDA Black Box Warning
None.
| Common Effects | Headache Muscle pain Upset stomach Back pain Nasopharyngitis inflammation of the throat and nasal passages |
| Serious Effects |
["Hypersensitivity to edrophonium or any component of the formulation.","Mechanical intestinal or urinary obstruction.","Patients receiving depolarizing neuromuscular blockers (e.g., succinylcholine) due to risk of prolonged apnea."]
| Precautions | ["Bradycardia and asystole have been reported; atropine should be readily available.","May cause bronchoconstriction in asthmatic patients.","Use with caution in patients with coronary artery disease, arrhythmias, or vagotonia.","Overdosage can cause cholinergic crisis with muscle weakness and respiratory paralysis."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal heart rate, respiratory status, and signs of cholinergic crisis. Fetal heart rate monitoring during administration in pregnancy, especially for bradycardia. Assess for neonatal transient myasthenia or cholinergic symptoms after delivery if used near term. |
| Fertility Effects | No evidence of impaired fertility in animal studies. No human data available. Cholinergic modulation may theoretically affect sperm motility or ovulation, but not clinically significant. |